Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CEeDD: Sonosensitive particles and ultrasound to enhance drug delivery in metastatic colorectal cancer

CEeDD Logo

 

 

 

 

 

 

 

 

Funding

Updated NIHR logo - April 2022.png

This study/project is funded by the National Institute for Health and Care Research (NIHR) [i4i PDA (NIHR201655)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care

Full Title

CEeDD: A First-in-Human Clinical Investigation of Cavitation-Enhanced Drug Delivery to Solid Tumours by co-Administration of Sonosensitive Particles and Application of Extracorporeal Ultrasound in Patients with Colorectal Metastases to the Liver

Chief Investigator: Prof. Rachel Kerr

Sponsor: University of Oxford

Study Status

Open to Recruitment

Study Design

Cohort 1: dose escalation (3+3+3) design.

Cohort 2: Group allocation 2-arm (6+6) Proof of Concept study.

Cohort 3: Randomised (12+12) early efficacy and feasibility study.

Study Population

Metastatic colorectal cancer

Study Schema

CEeDD_Chrt1_Safety_-1_Schema.jpg

 

CEeDD_Chrt1_Safety_0_Schema.jpg

 

CEeDD_Chrt1_ Safety_+1_Schema.jpg

 

CEeDD_Cohort2_Performance_Schema.png

CEeDD_Cohort3_Efficacy_Schema.png

 

 

Study Status

RECRUITING

TARGET RECRUITMENT Total 45-48 patients (Cohort 1: 9-12, Cohort 2: 12, Cohort 3: 24)

Cohort 1 has been COMPLETED

PARTICIPATING SITES

Churchill Hospital – Oxford University Hospital NHS Trust,

Queen Elizabeth Hospital - University Hospitals Birmingham (recruiting to Cohort 2 only)

Inclusion/Exclusion Criteria

Inclusion/Exclusion criteria Cohort 1 (SAFETY)

Inclusion criteria Cohort 1 (SAFETY):

A patient will be eligible for inclusion in this study if all of the following criteria apply.

  1. At least 1 confirmed CRC liver metastasis >1cm in diameter that is geographically-accessible to SonoTran intervention
  2. ≥ 18 years of age.
  3. Written (signed and dated) informed consent and be capable of cooperating with treatment and follow-up.
  4. Haematological and biochemical indices within the ranges shown below within 14 days prior to enrolment:

 

Lab Test

Value required

Haemoglobin (Hb)

≥ 9.0 g/dL (can be transfused to this value)

Absolute neutrophil count

≥ 1.5 x 109/L

Platelet count

≥ 100 x 109/L

Serum bilirubin

≤ 1.5 x upper limit of normal (ULN)

Alanine aminotransferase (ALT)

≤ 5 x ULN

Aspartate aminotransferase (AST)

≤ 5 x ULN

Serum creatinine

≤ 1.5 x ULN

PT and APTT

≤ 1.25x ULN

Albumin

≥ 28g/L

  1. Female subjects of childbearing potential must have negative pregnancy test within 14 days prior to SonoTran intervention.
  2. Patients with a diagnosis of mCRC, who are either not eligible to receive the standard of care chemotherapy or who have exhausted all lines of standard of care; or who are presently on a planned break from SOC chemotherapy.
  3. ECOG performance status of 0, 1 or 2.

 

Exclusion criteria Cohort 1 (SAFETY):

A patient will not be eligible for the study if any of the following apply:

  1. Any active anti-cancer therapy (chemotherapy / small molecule inhibitors / immunotherapy) within 4 weeks or liver radiotherapy within 8 weeks, prior to planned intervention in the study.
  2. Persistent, unresolved CTCAE v5.0 Grade 2 or higher drug-related toxicity (except alopecia, erectile dysfunction, hot flashes, decreased libido, chronic neuropathy) following previous treatment.
  3. Inadequate recovery from any prior surgical procedure or major surgical procedure performed within 4 weeks prior to enrolment.
  4. Any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with the subject's participation in the clinical investigation or interfere with the interpretation of clinical investigation results.
  5. Serious/symptomatic active infection or infection requiring antibiotics, within 7 days prior to enrolment.
  6. Presence of active cholangitis.
  7. Known Human Immunodeficiency Virus (HIV) infection or a known HIV-related malignancy.
  8. Known bleeding diathesis.
  9. Inability to comply with the protocol requirements.
  10. Participation in any other clinical trials involving therapeutic agents within the last 4 weeks prior to enrolment.
  11. Pregnant or lactating females.
  12. Patients with liver metastases eligible for immediate surgical resection or other radical therapy such as ablation, unless these interventions are not expected to occur within the next 8 weeks, allowing participation in the study and completion of follow-up, prior to that specified intervention

Inclusion/Exclusion criteria Cohort 2 (PERFORMANCE)

Inclusion criteria Cohort 2 (PERFORMANCE):

A patient will be eligible for inclusion in this study if all of the following criteria apply.

  1. At least 1 colorectal liver metastasis that is planned to be resected, with or without neo-adjuvant chemotherapy. The tumour measures at least 1 cm in diameter on the pre-operative radiological imaging.
  2. The metastasis(es) can be geographically inaccessible to SonoTran intervention as long as there are still spaces in Cohort 2A of the study (i.e. drugs alone prior to surgical resection). If there are no spaces on Arm 2A and spaces still remain on Arm 2B, the patients will require to have at least one geographically-accessible lesion amenable to SonoTran intervention.
  3. If the patient has received neoadjuvant chemotherapy, at least 1 tumour of more than 1cm diameter must remain radiologically visible on post-chemotherapy imaging, and 4 weeks must have elapsed from end of neoadjuvant chemotherapy and planned surgery (as per standard clinical practice).
  4. If there is disease outside of the liver, there must be a plan to eradicate this e.g. by surgery, ablation or SABR treatment as part of the curative strategy (as per standard clinical practice).
  5. ≥ 18 years of age.
  6. Written (signed and dated) informed consent and be capable of cooperating with treatment and follow-up.
  7. Haematological and biochemical indices within the ranges shown below within 14 days prior to enrolment:

 

Lab Test

Value required

Haemoglobin (Hb)

≥ 9.0 g/dL (can be transfused to this value)

Absolute neutrophil count

≥ 1.5 x 109/L

Platelet count

≥ 100 x 109/L

Serum bilirubin

≤ 1.5 x upper limit of normal (ULN)

Alanine aminotransferase (ALT)

≤ 5 x ULN

Aspartate aminotransferase (AST)

≤ 5 x ULN

Serum creatinine

≤ 1.5 x ULN

PT and APTT

≤ 1.25x ULN

Albumin

≥ 28g/L

  1. Female subjects of childbearing potential must have negative pregnancy test within 14 days prior to SonoTran intervention.
  2. ECOG performance status of 0 or 1.
  3. Female subjects of childbearing potential and male subjects whose sexual partners are of childbearing potential must agree to abstain from sexual intercourse or to use an effective method of contraception during the study and up to 6 months after the end of study. Examples of effective methods of contraception include oral or injected contraceptives or double barrier methods such as condom plus spermicide or condom plus diaphragm.

Exclusion criteria Cohort 2 (PERFORMANCE):

A patient will not be eligible for the study if any of the following apply:

  1. Any active anti-cancer therapy (chemotherapy / small molecule inhibitors / immunotherapy) within 4 weeks or liver radiotherapy within 8 weeks, prior to SonoTran intervention.
  2. Persistent, unresolved CTCAE v5.0 Grade 2 or higher drug-related toxicity (except alopecia, erectile dysfunction, hot flashes, decreased libido, chronic neuropathy) following previous treatment, that might interfere with the ability to give the small doses of the planned drugs.
  3. Inadequate recovery from any prior surgical procedure or major surgical procedure performed within 4 weeks prior to enrolment.
  4. Any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with the subject's participation in the clinical investigation or interfere with the interpretation of clinical investigation results.
  5. Serious/symptomatic active infection or infection requiring antibiotics, within 7 days prior to enrolment.
  6. Presence of active cholangitis.
  7. Known Human Immunodeficiency Virus (HIV) infection with CD4+ count of <350 cells/uL or history of AIDS-defining illness.
  8. Known uncontrolled bleeding diathesis.
  9. Inability to comply with the protocol requirements.
  10. Participation in any other clinical trials involving therapeutic agents within the last 4 weeks prior to enrolment.
  11. Pregnant or lactating females.
  12. Known UGT-1A1 polymorphism.

Inclusion/Exclusion criteria Cohort 3 (EFFICACY)

Inclusion criteria Cohort 3 (EFFICACY):

A patient will be eligible for inclusion in this study if all of the following criteria apply.

  1. At least 1 confirmed CRC liver metastasis >1cm in diameter, and metastatic disease that is NOT planned to be IMMEDIATELY resected or ablated.
  2. As patients will be allocated within this cohort, the metastasis(es) can be geographically inaccessible to SonoTran intervention as long as there are still spaces in Cohort 3A of the study (i.e. drugs alone). If there are no spaces on Arm 3A and spaces still remain on Arm 3B, the patients will require to have at least one geographically-accessible lesion amenable to SonoTran intervention.
  3. Not previously received cetuximab or irinotecan for metastatic colorectal cancer.
  4. ≥ 18 years of age.
  5. Written (signed and dated) informed consent and be capable of cooperating with treatment and follow-up.
  6. Haematological and biochemical indices within the ranges shown below within 14 days prior to enrolment:

Lab Test

Value required

Haemoglobin (Hb)

≥ 9.0 g/dL (can be transfused to this value)

Absolute neutrophil count

≥ 1.5 x 109/L

Platelet count

≥ 100 x 109/L

Serum bilirubin

≤ 1.5 x upper limit of normal (ULN)

Alanine aminotransferase (ALT)

≤ 5 x ULN

Aspartate aminotransferase (AST)

≤ 5 x ULN

Serum creatinine

≤ 1.5 x ULN

PT and APTT

≤ 1.25x ULN

Albumin

≥ 28g/L

  1. Confirmed RAS wild-type CRC
  2. Female subjects of childbearing potential must have negative pregnancy test within 14 days prior to SonoTran intervention.
  3. ECOG performance status of 0 or 1.
  4. Female subjects of childbearing potential and male subjects whose sexual partners are of childbearing potential must agree to abstain from sexual intercourse or to use an effective method of contraception during the study and up to 6 months after the end of study. Examples of effective methods of contraception include oral or injected contraceptives or double barrier methods such as condom plus spermicide or condom plus diaphragm.

Exclusion criteria Cohort 3 (EFFICACY):

A patient will not be eligible for the study if any of the following apply:

  1. Metastatic disease outside of the liver that is reasonably expected to cause acute deterioration or death within 14 weeks of entry in to the study i.e. the patient’s life expectancy should be at least 14 weeks in order to allow completion of protocolled intervention and primary endpoint read-out.
  2. Any active anti-cancer therapy (chemotherapy / small molecule inhibitors / immunotherapy) within 4 weeks or liver radiotherapy within 8 weeks, prior to SonoTran intervention.
  3. Persistent, unresolved CTCAE v5.0 Grade 2 or higher drug-related toxicity (except alopecia, erectile dysfunction, hot flashes, decreased libido, chronic neuropathy) following previous treatment.
  4. Inadequate recovery from any prior surgical procedure or major surgical procedure performed within 4 weeks prior to enrolment.
  5. Any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with the subject's participation in the clinical investigation or interfere with the interpretation of clinical investigation results.
  6. Serious/symptomatic active infection or infection requiring antibiotics, within 7 days prior to enrolment.
  7. Presence of active cholangitis.
  8. Known Human Immunodeficiency Virus (HIV) infection with CD4+ count of <350 cells/uL or history of AIDS-defining illness.
  9. Known uncontrolled bleeding diathesis.
  10. Inability to comply with the protocol requirements.
  11. Participation in any other clinical trials involving therapeutic agents within the last 4 weeks prior to enrolment.
  12. Patients with history of QT prolongation, clinically significant VT, VF, heart block, myocardial infarction within 6 months, CHF NYHA Class III or IV, unstable angina.
  13. Pregnant or lactating females.
  14. Known homozygous (i.e. complete) DPD deficiency or UGT-1A1 polymorphism (patients with DPD functional activity of at least 0.5, where within standard clinical practice they would receive 50% 5FU, will be eligible).
  15. Patients with liver metastases that are IMMEDIATELY amenable to surgical resection without neoadjuvant treatment.
  16. Patients for whom IMMEDIATE ablation is planned by MDT.

Primary Objective

Cohort 1 (SAFETY): To assess whether the SonoTran Platform is capable of inducing detectable and reproducible inertial cavitation activity in the target tumour during the intervention

Cohort 2 (PERFORMANCE): To assess the safety of a single small dose of drugs when combined with the use of SonoTran Platform pre-liver resection compared to giving the drugs alone.

Cohort 3 (EFFICACY): To assess the safety of the repeated use of the SonoTran Platform performed synchronously with multiple administrations of cetuximab antibody and FOLFIRI chemotherapy.

To assess whether the addition of the SonoTran Platform increases conversion to resectability of those patients whose liver metastases are not resectable initially.

Key Dates

1st patient recruited by 31Dec2021

Cohort 1 recruitment completed on 19Oct2022

Cohort 2 & 3 Open for recruitment on 22Nov2022

On this page